Edition:
India

GlaxoSmithKline PLC (GSK.N)

GSK.N on New York Stock Exchange

42.52USD
22 Oct 2019
Change (% chg)

$-0.08 (-0.19%)
Prev Close
$42.60
Open
$42.85
Day's High
$43.09
Day's Low
$42.50
Volume
614,253
Avg. Vol
465,945
52-wk High
$43.22
52-wk Low
$36.42

Latest Key Developments (Source: Significant Developments)

GlaxoSmithKline Posts Q2 Adjusted EPS 30.5 Pence
Wednesday, 24 Jul 2019 

July 24 (Reuters) - Glaxosmithkline Plc ::Q2 ADJUSTED EPS ROSE 9 PERCENT TO 30.5 PENCE.QTRLY TOTAL EPS 19.5P.2019 ADJUSTED EPS GUIDANCE IMPROVED TO EXPECTED DECLINE OF -3% TO -5% AT CER FROM -5% TO -9%.19P DIVIDEND DECLARED FOR QUARTER; CONTINUE TO EXPECT 80P FOR FY19.QTRLY GROUP SALES £7.8 BILLION, +7% AER, +5% CER.QTRLY ADJUSTED EPS 30.5P.NEW GUIDANCE REFLECTS IMPROVED OPERATING PERFORMANCE, LOWER INTEREST EXPENSE, ONE-OFF BENEFIT TO SHARE OF AFTER TAX PROFITS OF ASSOCIATES IN Q1.QTRLY PHARMACEUTICALS SALES £4.3 BILLION, +2% AER, -1% CER.POSITIVE CLINICAL DATA RECEIVED SO FAR THIS YEAR OFFER SIGNIFICANT NEW OPPORTUNITIES FOR PRODUCTS IN ONCOLOGY, HIV, RESPIRATORY.QTRLY VACCINES SALES £1.6 BILLION, +26% AER, +23% CER.SHINGRIX RECORDED SALES OF £386 MILLION IN THE QUARTER, DRIVEN BY CONTINUED STRONG UPTAKE IN THE US.QTRLY CONSUMER HEALTHCARE SALES £1.9 BILLION, +5% AER, +4% CER.IF EXCHANGE RATES HOLD AT CLOSING RATES ON 30 JUNE FOR REST OF 2019, ESTIMATED POSITIVE IMPACT ON 2019 STERLING TURNOVER GROWTH TO BE ABOUT 2%.EXPECT TO COMPLETE JOINT VENTURE WITH PFIZER SHORTLY.QTRLY TURNOVER INCREASED 5% CER WITH CER GROWTH DELIVERED BY VACCINES, CONSUMER HEALTHCARE PARTIALLY OFFSET BY DECLINE IN PHARMACEUTICALS.QTRLY HIV SALES £1.2 BILLION +2% AER, -2% CER.QTRLY SALES OF ESTABLISHED PHARMACEUTICALS DECLINED 6% AER, 7% CER TO £2,138 MILLION INCLUDING IMPACT OF LOSS OF EXCLUSIVITY OF ADVAIR.TOTAL MAJOR RESTRUCTURING CHARGES INCURRED IN QUARTER WERE £309 MILLION (Q2 2018: £158 MILLION).  Full Article

GSK Says Co To Announce Collaboration With Lyell Immunopharma
Wednesday, 24 Jul 2019 

July 24 (Reuters) - GlaxoSmithKline PLC ::SAYS "SHINGRIX HAD ANOTHER STANDOUT QUARTER" - CONF CALL.SAYS MORE THAN DOUBLED THE NUMBER OF ASSETS IN ONCOLOGY OVER THE LAST 12 MONTHS - MEDIA CALL.HAL BARRON SAID ON THE MEDIA CALL THAT THE COMPANY WILL ANNOUNCE A COLLABORATION WITH LYELL IMMUNOPHARMA.GSK, WITH RESPECT TO BREXIT, SAYS NOTHING HAS REALLY CHANGED AND WE CONTINUE TO PREPARE FOR ALL SCENARIOS - CONF CALL.SAYS NO-DEAL BREXIT WOULD BE A BAD SCENARIO - CONF CALL.GSK CEO, WITH RESPECT TO BREXIT, SAYS STAND READY TO WORK WITH BRITISH GOVERNMENT - CONF CALL.  Full Article

GSK Names Jonathan Symonds As Non-Executive Chairman Of Board Of Directors
Wednesday, 24 Jul 2019 

July 24 (Reuters) - GlaxoSmithKline PLC ::GLAXOSMITHKLINE PLC HSBC HOLDINGS PLC - NON-EXECUTIVE CHAIRMAN.GLAXOSMITHKLINE PLC - GLAXOSMITHKLINE PLC APPOINTS JONATHAN SYMONDS AS NON-EXECUTIVE CHAIRMAN OF BOARD OF DIRECTORS.GLAXOSMITHKLINE - JONATHAN SYMONDS WILL SUCCEED SIR PHILIP HAMPTON AS NON-EXECUTIVE CHAIRMAN OF GSK BOARD.  Full Article

HSBC Says Jonathan Symonds To Reitre As Independent Non-Executive Director
Wednesday, 24 Jul 2019 

July 24 (Reuters) - 0005.HK <0005.HK>::DIRECTOR DECLARATION AND RETIREMENT OF DIRECTOR.JONATHAN SYMONDS, INDEPENDENT NON-EXECUTIVE DIRECTOR OF HSBC HOLDINGS PLC ( "COMPANY"), HAS BEEN APPOINTED AS NON-EXECUTIVE CHAIRMAN OF GSK.  Full Article

GSK Poised To Name Jonathan Symonds As Its Next Chairman- Bloomberg
Sunday, 14 Jul 2019 

July 14 (Reuters) - :GLAXOSMITHKLINE PLC IS POISED TO NAME JONATHAN SYMONDS AS ITS NEXT CHAIRMAN- BLOOMBERG, CITING A SOURCE.  Full Article

GSK Says ViiV Switch Study Shows 2DR As Effective As 3DR
Wednesday, 10 Jul 2019 

July 10 (Reuters) - GlaxoSmithKline PLC ::GLAXOSMITHKLINE PLC - VIIV SWITCH STUDY SHOWS 2DR AS EFFECTIVE AS 3DR.GLAXOSMITHKLINE PLC - PHASE III HIV STUDY MEETS PRIMARY ENDPOINT.GSK- STUDY SHOWED ABILITY TO CONTROL HIV-1 WITH REGIMEN OF DOLUTEGRAVIR+LAMIVUDINE IN VIRALLY SUPPRESSED PATIENTS SWITCHING FROM 3-DRUG REGIMEN.GLAXOSMITHKLINE PLC - STUDY MET ITS PRIMARY ENDPOINT FOR NON-INFERIORITY.GLAXOSMITHKLINE PLC - SAFETY RESULTS FOR 2DR OF DOLUTEGRAVIR PLUS LAMIVUDINE WERE CONSISTENT WITH PRODUCT LABELLING FOR MEDICINES.GSK - NO PATIENTS MET CONFIRMED VIROLOGIC WITHDRAWAL CRITERIA OR DEVELOPED TREATMENT RESISTANCE IN DOLUTEGRAVIR PLUS LAMIVUDINE ARM OF STUDY.  Full Article

Springworks Therapeutics Announces Global Clinical Collaboration With GlaxoSmithKline
Thursday, 27 Jun 2019 

June 27 (Reuters) - :SPRINGWORKS THERAPEUTICS ANNOUNCES GLOBAL CLINICAL COLLABORATION WITH GLAXOSMITHKLINE TO EVALUATE NIROGACESTAT IN COMBINATION WITH BELANTAMAB MAFODOTIN IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA.SPRINGWORKS - GLAXOSMITHKLINE WILL SPONSOR & CONDUCT ADAPTIVE PHASE 1B STUDY TO EVALUATE SAFETY, TOLERABILITY & PRELIMINARY EFFICACY OF COMBINATION.SPRINGWORKS THERAPEUTICS - GLAXOSMITHKLINE WILL ASSUME ALL DEVELOPMENT COSTS ASSOCIATED WITH STUDY.SPRINGWORKS THERAPEUTICS - GLAXOSMITHKLINE, CO WILL ALSO FORM JOINT DEVELOPMENT COMMITTEE TO MANAGE CLINICAL STUDY.  Full Article

Liquidia And Gsk Restructure Collaboration Agreement
Thursday, 27 Jun 2019 

June 26 (Reuters) - GlaxoSmithKline PLC ::LIQUIDIA AND GSK RESTRUCTURE COLLABORATION AGREEMENT.LIQUIDIA - AMENDED AGREEMENT PROVIDES COMPANY WITH THE RIGHT TO DEVELOP AND COMMERCIALIZE THREE ADDITIONAL PRINT-BASED THERAPEUTICS.LIQUIDIA TECHNOLOGIES - CAN BUY RIGHTS TO PURSUE ADDITIONAL PRINT-BASED PROGRAMS FOR INHALATION THERAPY, SUBJECT TO GSK'S APPROVAL.LIQUIDIA TECHNOLOGIES - ANY NEW PRINT-BASED THERAPEUTIC DELIVERED VIA INHALATION DEVELOPED BY CO WOULD CARRY MILESTONE & ROYALTY OBLIGATIONS DUE TO GSK.LIQUIDIA- AMENDED DEAL PROVIDES GSK WITH RIGHT OF FIRST NEGOTIATION PRIOR TO CO ENTERING INTO LICENSE DEAL WITH 3RD PARTY FOR ANY GSK-APPROVED PROGRAM.LIQUIDIA - ANY NEW PRINT-BASED THERAPEUTIC DELIVERED VIA INHALATION DEVELOPED BY CO UNDER AMENDED DEAL WOULD CARRY MILESTONE, ROYALTY OBLIGATIONS DUE.  Full Article

GSK Says FDA Accepts Application For Zejula In Ovarian Cancer With Priority Review
Monday, 24 Jun 2019 

June 24 (Reuters) - GlaxoSmithKline PLC ::SAYS U.S. FDA ACCEPTS APPLICATION FOR ZEJULA (NIRAPARIB) IN LATE STAGE OVARIAN CANCER WITH PRIORITY REVIEW.SAYS THE SUPPLEMENTAL NEW DRUG APPLICATION FOR ZEJULA (NIRAPARIB) HAS AN ACTION DATE OF 24 OCTOBER 2019.  Full Article

GSK Says Nucala (Mepolizumab) Gains U.S. FDA Approval For Two New Self-Administration Options
Friday, 7 Jun 2019 

June 6 (Reuters) - GlaxoSmithKline PLC ::GLAXOSMITHKLINE SAYS NUCALA (MEPOLIZUMAB) GAINS U.S. FDA APPROVAL FOR TWO NEW SELF-ADMINISTRATION OPTIONS.  Full Article

TIMELINE-Popular heartburn medicine Zantac pulled off store shelves

Oct 21 The U.S. Food and Drug Administration and international health authorities are investigating the safety of Zantac heartburn medicine, also sold generically as ranitidine, after finding a probable cancer-causing impurity in the drug.